Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Haley Zlomke"'
Autor:
Richard A. Burkhart, Elizabeth M. Jaffee, David T. Ting, Theodore S. Hong, Alec C. Kimmelman, David P. Ryan, James R. Eshlemann, David A. Tuveson, Lei Zheng, Ying S. Zou, Christopher L. Wolfgang, Jin He, Kelly J. Lafaro, William R. Burns, John L. Cameron, Christopher R. Shubert, Annamaria Szabolcs, Gabriel D. Ivey, Haley Zlomke, Reecha Suri, Jacquelyn W. Zimmerman, Toni T. Seppälä
Purpose:Patient-derived organoids (PDO) are a promising technology to support precision medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may improve clinical next-generation sequencing (NGS) and enable rapid ex viv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62beab9186a15d7514a21213d9c78c4b
https://doi.org/10.1158/1078-0432.c.6532688
https://doi.org/10.1158/1078-0432.c.6532688
Autor:
Richard A. Burkhart, Elizabeth M. Jaffee, David T. Ting, Theodore S. Hong, Alec C. Kimmelman, David P. Ryan, James R. Eshlemann, David A. Tuveson, Lei Zheng, Ying S. Zou, Christopher L. Wolfgang, Jin He, Kelly J. Lafaro, William R. Burns, John L. Cameron, Christopher R. Shubert, Annamaria Szabolcs, Gabriel D. Ivey, Haley Zlomke, Reecha Suri, Jacquelyn W. Zimmerman, Toni T. Seppälä
Supplementary Figure from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10d802fe835389dfd1182810c9aebaf9
https://doi.org/10.1158/1078-0432.22488263.v1
https://doi.org/10.1158/1078-0432.22488263.v1
Autor:
Richard A. Burkhart, Elizabeth M. Jaffee, David T. Ting, Theodore S. Hong, Alec C. Kimmelman, David P. Ryan, James R. Eshlemann, David A. Tuveson, Lei Zheng, Ying S. Zou, Christopher L. Wolfgang, Jin He, Kelly J. Lafaro, William R. Burns, John L. Cameron, Christopher R. Shubert, Annamaria Szabolcs, Gabriel D. Ivey, Haley Zlomke, Reecha Suri, Jacquelyn W. Zimmerman, Toni T. Seppälä
Supplementary Table from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091771dfdac975d3a04a587819e44c33
https://doi.org/10.1158/1078-0432.22488257
https://doi.org/10.1158/1078-0432.22488257
Autor:
Richard A. Burkhart, Elizabeth M. Jaffee, David T. Ting, Theodore S. Hong, Alec C. Kimmelman, David P. Ryan, James R. Eshlemann, David A. Tuveson, Lei Zheng, Ying S. Zou, Christopher L. Wolfgang, Jin He, Kelly J. Lafaro, William R. Burns, John L. Cameron, Christopher R. Shubert, Annamaria Szabolcs, Gabriel D. Ivey, Haley Zlomke, Reecha Suri, Jacquelyn W. Zimmerman, Toni T. Seppälä
Supplementary Data from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505ae6583ccc30f322e8dcfaf59c3cd9
https://doi.org/10.1158/1078-0432.22488281
https://doi.org/10.1158/1078-0432.22488281
Autor:
Toni T. Seppälä, Jacquelyn W. Zimmerman, Reecha Suri, Haley Zlomke, Gabriel D. Ivey, Annamaria Szabolcs, Christopher R. Shubert, John L. Cameron, William R. Burns, Kelly J. Lafaro, Jin He, Christopher L. Wolfgang, Ying S. Zou, Lei Zheng, David A. Tuveson, James R. Eshlemann, David P. Ryan, Alec C. Kimmelman, Theodore S. Hong, David T. Ting, Elizabeth M. Jaffee, Richard A. Burkhart
Publikováno v:
Clin Cancer Res
Purpose: Patient-derived organoids (PDO) are a promising technology to support precision medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may improve clinical next-generation sequencing (NGS) and enable rapid ex vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e8d61b4133e7ad0662dc20817faba1
https://europepmc.org/articles/PMC9357072/
https://europepmc.org/articles/PMC9357072/
Autor:
Benedict Kinny-Köster, Samantha Guinn, Joseph A. Tandurella, Jacob T. Mitchell, Dimitrios N. Sidiropoulos, Melanie Loth, Melissa R. Lyman, Alexandra B. Pucsek, Toni T. Seppälä, Christopher Cherry, Reecha Suri, Haley Zlomke, Jin He, Christopher L. Wolfgang, Jun Yu, Lei Zheng, David P. Ryan, David T. Ting, Alec Kimmelman, Anuj Gupta, Ludmila Danilova, Jennifer H. Elisseeff, Laura D. Wood, Genevieve Stein-O’Brien, Luciane T. Kagohara, Elizabeth M. Jaffee, Richard A. Burkhart, Elana J. Fertig, Jacquelyn W. Zimmerman
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by a heterogeneous tumor microenvironment (TME) that is enriched with cancer associated fibroblasts (CAFs)1. Cell-cell interactions involving these CAFs promote an immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cc5107abd96598f6c594da5251e9ad2
https://doi.org/10.1101/2022.07.14.500096
https://doi.org/10.1101/2022.07.14.500096
Autor:
Jianxin Wang, May Tun Saung, Keyu Li, Juan Fu, Kenji Fujiwara, Nan Niu, Stephen Muth, Junke Wang, Yao Xu, Noah Rozich, Haley Zlomke, Sophia Chen, Birginia Espinoza, MacKenzie Henderson, Vanessa Funes, Brian Herbst, Ding Ding, Christina Twyman-Saint Victor, Qihong Zhao, Amol Narang, Jin He, Lei Zheng
Publikováno v:
Journal of Experimental Medicine. 219
The resistance of pancreatic ductal adenocarcinoma (PDAC) to immune checkpoint inhibitors (ICIs) is attributed to the immune-quiescent and -suppressive tumor microenvironment (TME). We recently found that CCR2 and CCR5 were induced in PDAC following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8b4d12f083293e2998af27723d3228c
https://doi.org/10.1084/jem.20211631
https://doi.org/10.1084/jem.20211631
Autor:
A D Pinnola, Will Lancaster, David B. Adams, Ryan Gedney, Elizabeth Winter, John Craver, Shelby Allen, Haley Zlomke, Doris Kim
Publikováno v:
Surgical endoscopy. 35(8)
Gastroparesis is a condition characterized by impaired gastric motility that may result in weight loss and malnutrition. There have been promising studies demonstrating improvement in symptoms after gastric electrical stimulation (GES) implantation f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e92ec73525752211de86006d67f1b0b
https://pubmed.ncbi.nlm.nih.gov/32909214
https://pubmed.ncbi.nlm.nih.gov/32909214